ReviewEuropean journal of medical research2025
Lactate and gastric cancer immunotherapy from regulatory mechanisms to therapeutic strategies: a critical review.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy.Clinical and translational medicine · 2026Review
- Protein Lactylation in Central Nervous System Diseases: Molecular Mechanisms and Targeted Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Integrative Mendelian Randomization and Pathomics Analysis Using Expression Quantitative Trait Loci and Genome-Wide Association Study Data Identifies Mismatch Repair Genes as Prognostic Biomarkers in Gastric Adenocarcinoma.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGastric cancer (GC) remains a leading cause of cancer-related mortality globally, with current immunotherapies exhibiting limited therapeutic efficacy owing to the immunosuppressive tumour microenvironment (TME). MAIN BODY: Lactate, a hallmark metabolic by-product of tumour glycolysis, also functions as a critical metabolic driver. By promoting TME acidification, immunosuppression, and epigenetic reprogramming, lactate emerges as a pivotal regulator in reshaping GC immune evasion and therapeutic resistance, while also strongly correlating with chemotherapy resistance. Furthermore, the dysregulated expression of lactate-associated metabolic genes represents a promising therapeutic target.
conclusionThis review elucidates the dual roles and clinical value of lactate in gastric cancer as both an energy substrate and a signalling molecule within the tumour microenvironment and positions lactylation as a critical metabolic-epigenetic bridge. We also discuss innovative strategies that integrate lactate metabolism-targeting immune checkpoint inhibitors to overcome therapeutic resistance in GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.